In vitro and in vivo identification of ABCB1 as an efflux transporter of bosutinib

BACKGROUND: Bosutinib is a recently approved ABL inhibitor. In spite of the well-documented effectiveness of BCR-ABL inhibitors in treating chronic myeloid leukemia, development of resistance is a continuous clinical challenge. Transporters that facilitate drug uptake and efflux have been proposed a...

Descripción completa

Detalles Bibliográficos
Autores principales: Redaelli, Sara, Perini, Pietro, Ceccon, Monica, Piazza, Rocco, Rigolio, Roberta, Mauri, Mario, Boschelli, Frank, Giannoudis, Athina, Gambacorti-Passerini, Carlo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2015
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4491863/
https://www.ncbi.nlm.nih.gov/pubmed/26149173
http://dx.doi.org/10.1186/s13045-015-0179-4

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4491863/
https://www.ncbi.nlm.nih.gov/pubmed/26149173
http://dx.doi.org/10.1186/s13045-015-0179-4

Ejemplares similares